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Translational relevance:  42 
The introduction of adjuvant but toxic therapies for primary melanoma has highlighted the need to 43 
stratify patients based on improved prognostic and predictive biomarkers. We report a six-class 44 
transcriptomic signature generated from primary melanomas which predicted prognosis, notably in 45 
stage I disease. The signature demonstrated comparable prognostic value to that of sentinel node 46 
biopsy. When the six classes were applied to published transcriptomic datasets from patients treated 47 
with immunotherapy, one class consistently predicted poor outcome. This class was characterised by 48 
expression of JUN and AXL, both known determinants of poor therapeutic response in advanced 49 
melanoma. These findings suggest that the six-class signature should be applied to larger datasets as 50 
they become available, in order to further validate its clinical relevance as a prognostic/predictive 51 





Previously identified transcriptomic signatures have been based on primary and metastatic 55 
melanomas with relatively few AJCC stage I tumors given difficulties in sampling small tumors. The 56 
advent of adjuvant therapies has highlighted the need for better prognostic and predictive biomarkers 57 
especially for AJCC stage I and II disease.  58 
Patients and Methods 59 
687 primary melanoma transcriptomes were generated from the Leeds Melanoma Cohort (LMC). The 60 
prognostic value of existing signatures across all the AJCC stages was tested. Unsupervised 61 
clustering was performed and the prognostic value of the resultant signature was compared with that 62 
of sentinel node biopsy (SNB) and tested as a biomarker in three published immunotherapy datasets. 63 
Results  64 




) but 65 
showed a significant interaction with AJCC stage (P=0.04) and did not predict outcome in stage I 66 
tumors (P=0.3 to 0.7). Consensus-based classification of the LMC dataset identified six classes which 67 
predicted outcome, notably in stage I disease. LMC class was a similar indicator of prognosis when 68 
compared to SNB and it added prognostic value to the genes reported by Gerami et al. One particular 69 
LMC class consistently predicted poor outcome in patients receiving immunotherapy in two of three 70 
tested datasets. Biological characterisation of this class revealed high JUN and AXL expression and 71 
evidence of epithelial to mesenchymal transition.  72 
Conclusion 73 
A transcriptomic signature of primary melanoma was identified with prognostic value, including in 74 
stage I melanoma and in patients undergoing immunotherapy. 75 
 76 




Cutaneous melanoma continues to increase in incidence worldwide. Although earlier diagnosis has 79 
been documented with correspondingly better outcomes, the rising incidence of thinner tumors means 80 
that, counterintuitively, one fifth of deaths now occur in patients presenting initially with early disease 81 
(1). In the UK, 91% of melanomas are diagnosed at AJCC stage I to II (2). Therefore, better 82 
prognostic biomarkers are needed to identify early stage disease requiring adjuvant therapies, as well 83 
as predictive biomarkers of response to checkpoint blockade. 84 
Previous transcriptomic analyses of cutaneous melanoma have generated gene signatures with a 85 
prognostic value independent of AJCC stage (3-7). The prognostic signature developed by Jonsson et 86 
al. (3) classifies metastatic melanomas into four classes (Lund 4-classes), later simplified into two 87 
classes (Lund 2-grades, (4)), and the signature developed by the TCGA (The Cancer Genome Atlas) 88 
consortium classified melanomas into three classes (TCGA 3-classes) (8). The prognostic 89 
significance of the Lund 4-class and TCGA 3-class signatures have been replicated in relatively small 90 
datasets, notably with few AJCC stage I patients (5,9). Another transcriptomic signature based on 27 91 
genes was developed by Gerami et al. (6) to classify primary melanoma patients into tumors which 92 
were high or low-risk for metastasis. 93 
 94 
In this study, the first aim was to test the prognostic value of the Lund and TCGA signatures, as well 95 
as the gene list of Gerami et al’s signature (6) in a large population-based cohort of primary 96 
melanomas with a good proportion of stage I patients and extensive phenotypic annotations (Leeds 97 
Melanoma Cohort, LMC). Since the dataset was well powered for discovery of novel tumor subtypes, 98 
unsupervised clustering of the tumor transcriptomes of the LMC was performed and the prognostic 99 
value of the resultant signature was compared with that of SNB in analyses stratified by AJCC stage. 100 
Finally, the association between the Leeds signature and outcome was tested in published data from 101 
patients receiving immunotherapy (10-12). 102 
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Materials and Methods 103 
Leeds Melanoma Cohort  104 
As described previously (13), 2184 primary melanoma patients were recruited to the Leeds Melanoma 105 
Cohort (LMC) in the period of 2000-2012. This was a population-ascertained cohort which therefore 106 
recruited patients treated at multiple clinical centres (recruitment rate 67%). During this period SNB 107 
was neither offered nor accepted universally. The study was ethically approved (ethical approval 108 
MREC 1/3/57, PIAG 3-09(d)/2003) and in accordance with the Declaration of Helsinki. Participants 109 
were consented to sampling of their FFPE (formalin fixed paraffin embedded) tumor blocks which 110 
were stored in the NHS (UK National Health Service) histopathology departments of the respective 111 
hospitals. Haemotoxylin and eosin (H&E)-stained slides were generated and examined to facilitate 112 
subsequent sampling of the blocks using a 0.6mm diameter tissue microarray needle as previously 113 
reported (5,13). Prior to sampling, all the tumor blocks were reviewed, and if there was only a small 114 
amount of tumor left in the block then the block was not sampled, lest a clinically important block be 115 
destroyed. Up to two cores were sampled from each block, and, to increase the comparability 116 
between tumors, the samples were consistently extracted from the least inflamed, least stromal 117 
regions of the invasive front of the tumor. The tumor infiltrating lymphocytes were scored using Clark 118 
et al.’s classification system (14). As previously reported (13), 703 tumor transcriptomes were profiled 119 
and in the current study 16 samples were removed in quality control leaving a cohort of 687 patients, 120 
henceforth referred to as the whole LMC dataset. The dataset contained 251 patients who had a SNB 121 
test (Supplementary table S10), and only 16 patients are known so far to have been treated with 122 
checkpoint blockade. The LMC patients were assigned an AJCC stage based on the AJCC staging 123 
8th edition (15). Where patients did not have a SNB, the AJCC staging used was derived from clinical 124 
staging and pathological examination of the wide local excision sample. 125 
mRNA extraction and expression data generation 126 
Both mRNA and DNA were extracted from the tumor samples derived from cores following a 127 
previously described protocol (5,13). The whole genome mRNA expression profiling was carried out 128 
using Illumina’s DASL-HT12-v4 array. As described previously, for quality control, the mRNA was 129 
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extracted from up to 2 cores for a number of patients (117 duplicates in total); gene expression data 130 
from only one extraction per patient was used in subsequent analyses (13). The raw transcriptomic 131 
data were extracted from the image files using GenomeStudio (Illumina Inc., San Diego) and were 132 
pre-processed as previously reported (13). Briefly, after background correction and quantile 133 
normalisation (R package LUMI (16)), singular value decomposition (SVD) was used to remove the 134 
batch effect (R package SWAMP (17)) (13). 135 
Quality control in LMC 136 
The array included 29,262 probes corresponding to 20,715 unique genes. For genes with multiple 137 
probes, the probe detected in the largest number of tumors was retained, and two additional filters 138 
were applied: genes had to be detected with P<0.05 in at least 40% of tumors and had to have a 139 
standard deviation (SD)>0.40. This SD threshold was chosen based on the overall distribution across 140 
the 20,715 genes on the log2 scale. The median SD was 0.68. The data were standardized to give 141 
each gene a mean of 0 and SD of 1.  142 
Procedures  143 
The LMC tumors were classified into the Lund 4-classes, Lund 2-grades and TCGA 3-classes using 144 
the supervised nearest centroid classification (NCC) as previously described (5). All the 27 genes of 145 
the Gerami et al. gene signature (6) were present in LMC dataset and were analysed using a 146 
univariable survival analysis in the whole LMC dataset and stage I tumors. Unsupervised clustering 147 
was performed using the consensus Partitioning Around Medoids clustering method in the R-package 148 
ConsensusClusterPlus (18,19) with Euclidean distance as the dissimilarity measure and a resampling 149 
fraction of 0.8 for both genes and samples in 1000 iterations (Supplementary methods). 150 
Statistical analysis  151 
Cox proportional hazard models and Kaplan-Meier curves were used to test the association with 152 
survival (R-package Survival) (20). The survival time was calculated from time of diagnosis to time of 153 
last follow-up or time of death from melanoma, whichever occurred first, referred to as melanoma-154 
specific survival (MSS). Patients with deaths caused by factors other than melanoma were censored 155 
at the time of death. Receiver Operating Characteristic (ROC) analysis was performed using AJCC 156 
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stage pre-SNB and AJCC stage post-SNB for patients who had SNB. Clinical staging prior to SNB is 157 
described as AJCC pre-SNB. The AJCC stage post-SNB includes additional information on regional 158 
lymph node metastasis. The analysis used AJCC staging 8
th
 edition, and MSS up to 3 years was 159 
chosen as cut-off based upon the inclusion of the majority of the deaths without loss of data as a 160 
result of censoring (Supplementary table S11). Patients who were censored before 3 years were not 161 
included in the analysis. The analysis was performed using R-packages pROC, plotROC, and ggplot2 162 
(21-23). 163 
Pathway enrichment analysis  164 
The differentially expressed genes (DEG) were identified using the Significance Analysis of 165 
Microarrays (R-package SAMR) by comparing each class versus all others (24). Pathway enrichment 166 
and biological network analysis of DEGs with a q-value equal to 0 were performed using 167 
ReactomeFiviz in Cytoscape (25). The central nodes of the biological network were identified using a 168 
centrality measure (betweenness) in Gephi (26) (Supplementary methods).  169 
Copy Number Alterations (CNA) 170 
The CNA data were generated in a subset of LMC tumors using Illumina’s next-generation 171 
sequencing platform as reported in Filia et al. (in revision) (Supplementary methods). Among the 687 172 
transcriptome-profiled patients of LMC, CNA data were available for 272 patients. The CNA were 173 
assessed in the regions spanning the genes identified as hubs in network enrichment analysis. The 174 
ratio between mean of the window read counts in the region mapping to a gene and the average read 175 
count of the 10 flanking regions around that gene was used to estimate the copy number changes. 176 
The windows (5k) corresponding to a gene locus were identified using the R packages biomaRt 177 
(27,28). The cut-off for calling a region amplified was chosen as a value greater than 0.4 while a value 178 
less than -0.4 was used to identify a deletion. The 272 samples in the CNA dataset were at AJCC 179 
stages I (n=80), II (n=147), and III (n=45) (similar distribution to the whole LMC dataset). 180 
Lund validation dataset 181 
For replication, a primary melanoma transcriptomic dataset of 223 tumors from a Lund cohort 182 
(Sweden) was used (Harbst et al. (4)). The samples were classified using the newly generated 183 
signature by the supervised NCC approach (5). Out of those 223 patients, 200 had recorded 184 
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information on melanoma relapse in the follow-up time post-diagnosis and were used to test the 185 
association between patient subgroups and relapse-free survival (using Cox proportional hazard 186 
models, Kaplan-Meier curves and log-rank test).  187 
 188 
Immunotherapy datasets 189 
Three publicly available transcriptome datasets (Hugo Cohort: GSE78220, Ulloa-Monotoya cohort: 190 
GSE35640, Riaz Cohort: https://github.com/riazn/bms038_analysis) were downloaded (10-12), 191 
samples were quantile normalised and classified using the NCC method (Pearson’s correlation 192 
coefficient). The Riaz cohort was a mixture of samples from various melanoma types (cutaneous 193 
melanoma, mucosal melanoma, acral melanoma, uveal/ocular melanoma, others). In this study the 194 
samples labelled as cutaneous melanoma were analysed. In all the three cohorts, the association with 195 
response to immunotherapy was tested using Fisher’s exact test. 196 
 197 
Results 198 
Existing signatures showed no association with survival in stage I 199 
melanoma  200 
The structure of datasets used in this study are depicted in Figure 1. When applied to the whole LMC 201 
dataset (n=687), the three formerly published signatures (Lund 4-class, Lund 2-grade, TCGA 3-class) 202 
replicated previously observed associations with MSS (Figure 2A, 2C, and 2E). However, upon 203 
stratifying LMC patients on the basis of AJCC stage, the Lund and TCGA signatures showed no 204 
association with prognosis for LMC stage I patients (Figure 2B, 2D, and 2F). The Lund 2-grade 205 
signature had the highest statistical power (since based on only two groups) and showed a 206 
statistically significant interaction with AJCC stage (P=0.02, Supplementary table S1), suggesting that 207 
the lack of association in stage I was not solely due to low sample size. Because the full details of 208 
Gerami et al’s (6) commercial signature were not published, we were limited in the scope of its 209 
replication in the LMC dataset. However, analysing the 27 Gerami genes identified 23 genes as 210 
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predictors of prognosis in the whole LMC dataset (Supplementary table S2). However, in keeping with 211 
the Lund and TCGA signatures, none of these genes showed a significant association with prognosis 212 
in stage I tumors (Supplementary table S2). 213 
 214 
Generating novel LMC classes and their clinical characteristics 215 
Consensus clustering of the LMC dataset was performed, and following additional quality control 216 
measures (Supplementary table S3), six distinct, novel molecular classes were identified (Figure 3A). 217 
These classes were associated with clinico-pathological variables known to have prognostic value, 218 
including tumor site (P=0.03), age at diagnosis (P=0.03), mitotic rate (P=0.002), ulceration (P=0.01), 219 
AJCC stage (P=6x10
-10
), tumor infiltrating lymphocytes (TILs) (P=6x10
-4
), and Breslow thickness 220 
(P=9x10
-14
) (Table 1). The LMC classes 1 and 5 tumors tended to be thin and non-ulcerated, whilst 221 
classes 2 and 4 tumors were thicker. Class 3 and 6 tumors were the thickest and most frequently 222 
ulcerated. The six classes showed strong association with BRAF (P=6x10
-5
) and NRAS mutation 223 
status (P=3x10
-4
): classes 1, 5, and 6 tumors were frequently BRAF mutated, while classes 2, 3, and 224 
4 tumors were frequently NRAS mutated (Table 1). 225 
 226 
LMC classes predicted prognosis in primary melanoma and in 227 
stage I subset 228 
The LMC classes predicted MSS in the whole LMC dataset and notably, across AJCC stages I, II and 229 
III subsets (Figure 3B-3C, Supplementary figure S1). In the unadjusted analysis of the whole dataset 230 
(Figure 3B, Supplementary table S4), class 1 (baseline) had the best prognosis, class 2 (HR=1.7, 231 
95% confidence interval (CI) 0.8-3.5) and class 5 (HR=1.5, 95% CI 0.7- 3.1) showed intermediate 232 
prognosis, while class 3 (HR=5.0, 95% CI 2.5-10.1), class 4 (HR=2.4, 95% CI 1.2- 4.7), and class 6 233 
(HR=3.1, 95% CI 1.6-6.1) had the worst prognosis. In multivariable analysis, classes 3, 4, and 6 234 
remained significant predictors of poor prognosis after including AJCC stage, sex, age at diagnosis, 235 
mitotic rate (Table S4) and when the AJCC stage was replaced by ulceration and Breslow thickness 236 
in the model (Table S6). In the LMC stage I subset, class 6 (HR=6.6, 95% CI 1.4-31.2) significantly 237 
predicted poor prognosis in unadjusted analysis (Figure 3C and Table S5) and it remained significant 238 
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when sex, age at diagnosis, mitotic rate, ulceration and Breslow thickness were adjusted (HR=9.8, 239 
95% CI 1.1-86.2, Table S6). Since Gerami signature was not available to us in full, we ran 240 
unsupervised clustering of the LMC dataset using the 27 Gerami genes to generate the 2 tumor 241 
groups analysed by Gerami et al. (6), referred to as the Gerami clusters. This analysis showed that 242 
the LMC classes and Gerami clusters had independent prognostic effects in the whole LMC dataset 243 
(Supplementary table S7); however, the Gerami clusters showed no prognostic value in stage I 244 
tumors while LMC class 6 remained a significant predictor in the multivariable model (Supplementary 245 
table S8). 246 
 247 
To validate the prognostic value of the LMC classes in an independent dataset, a 150-gene based 248 
signature (LMC signature), generated after refining ~13,000 genes (Supplementary figure S2), was 249 
applied to the Lund dataset (4). In keeping with the observations made in the LMC dataset, class 3, 250 
class 4, and class 6 predicted worse prognosis in the Lund dataset, while class 1, class 2, and class 5 251 
predicted better prognosis (Figure 3D, Supplementary table S9). Since the Lund dataset had only a 252 
few stage I cases (n=58) the prognostic value of LMC signature could not be replicated in stage I 253 
disease. 254 
LMC signature had independent prognostic value when compared 255 
with SNB  256 
In the dataset derived from individuals who had a SNB, the prognostic value of combined LMC class 257 
signature and pre-SNB AJCC stage was similar to that of AJCC stage with SNB (i.e. stage post-SNB) 258 
(AUC 0.82 vs 0.80, P= 0.7, Figure 3E). Combining the LMC signature with AJCC stage post-SNB, 259 
patient’s sex, age at diagnosis and site of tumor increased the AUC to 0.88. Similarly, in the subset of 260 
patients at stage I pre-SNB, the LMC signature alone had comparable prognostic value to AJCC 261 
stage post-SNB (AUC=0.88 vs 0.83, P= 0.7, Figure 3F). In this stage I subset, addition of stage post-262 
SNB, patient’s sex, age at diagnosis and site of tumor to the LMC signature further increased the 263 
AUC to 0.98. However, the limited sample size of stage I dataset and including so many variables 264 
clearly overfitted the model, giving near perfect classification and illustrating that independent 265 
datasets are needed to better assess performance. 266 
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Biological overlap between the LMC and existing signatures  267 
The six classes of LMC signature showed distinct gene expression profiles (Figure 4A) and showed 268 
partial overlap with the existing Lund and TCGA signatures. LMC classes 1, 3, and 5 overlapped 269 
substantially with the high-immune, pigmentation, and normal-like classes of the Lund 4-classes 270 
(Figure 4B), and with the immune, MITF low, and keratin classes of the TCGA 3-classes (Figure 4C). 271 
In contrast, LMC classes 2, 4, and 6 represented a mixture of the Lund 4-classes and TCGA 3-272 
classes. Gene expression pathway enrichment analysis revealed distinctive biological features of the 273 
6 LMC classes: notably class 2 was characterised by increased WNT signalling genes and metabolic 274 
pathways; class 4 by decreased expression of immune genes and class 6 by increased expression of 275 
cell cycle and consistent down-regulation of cell metabolism pathway genes (Supplementary table 276 
S14).  277 
When applied to the LMC 6 classes, the Lund modules (29) revealed discrimination consistent with 278 
enriched gene pathways: LMC class 1 tumors showed higher immune module activity, and class 3 279 
tumors showed higher cell cycle module activity (Figure 4D). Interestingly, class 6 tumors had 280 
relatively higher cell cycle but also immune module activity and, as expected, the immune, stroma and 281 
interferon modules were positively correlated but they negatively correlated with cell cycle and MITF 282 
modules (Figure 4D). The tumor infiltrating immune cell populations imputed for each of the LMC 283 
classes (30) were consistent with the Lund immune module, as class 1 had the highest immune cell 284 
populations and class 3 the lowest, whilst class 6 appeared to maintain an intermediate level of 285 
immune cell populations, having the second highest scores on average (Supplementary figure S3).  286 
A comparison with the Consensus Immunome Clusters (CICs), previously generated in the same 287 
LMC dataset based on 380 immune genes (13), showed that the 2 most prognostically contrasted 288 
LMC classes (class 1 and class 3) had a near perfect match with CIC 2 (high Immune) and CIC 3 (low 289 
immune/く-catenin high) respectively (Supplementary figure S4) while the rest of LMC classes were a 290 
mixture of CICs. Cluster 1 had correspondingly a higher proportion of tumors with histological 291 
evidence of brisk tumor infiltrating lymphocytes (36% compared with 8% in class 3). Analysing the 292 
correlation between the Gerami genes and LMC signature genes showed that the Gerami genes 293 
positively correlated with the genes upregulated in LMC class 5 tumors and negatively correlated with 294 
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genes upregulated in LMC class 3 tumors (Supplementary figure S5). Consistent with this, Gerami 295 
clusters 1 and 2 highly overlapped with LMC classes 3 and 5 respectively (Supplementary figure S6). 296 
JUN as marker of poor prognosis in class 6 tumors 297 
LMC class 6 predicted worse prognosis within AJCC stage I tumors. Further biological network 298 
analysis identified JUN as a key upregulated nodal gene in this class (Figure 5A-B). The NGS-based 299 
CNA data from a subset of LMC tumors (n=272) indicated that class 6 tumors were more likely to 300 
have DNA amplifications of JUN than other classes (P=0.003, Figure 5C, Supplementary figure S7). 301 
In melanoma, JUN has been reported to activate epithelial-to-mesenchymal transition (EMT), and 302 
accordingly a 6-gene based (31) and 200-gene based EMT signature (32) consistently scored higher 303 
in LMC class 6 than in all other LMC classes (Figure 5D, Supplementary figure S7). A secondary key 304 
nodal gene NFKB1 identified to be upregulated in class 6 had no copy number changes. Further 305 
examination of immunohistochemically stained sections, showed that all 4 tumors stained from class 306 
6 were positive for NFKB1 protein expression, and this was similar to other LMC classes (P=0.4, 307 
Supplementary figure S7). 308 
LMC signature as a potential predictor of response to 309 
immunotherapy 310 
The value of the LMC signature in predicting outcome in patients treated with immunotherapy was 311 
assessed in three disparate clinical trial cohorts of metastatic melanoma (Figure 5F) (10-12). In the 312 
Hugo et al. cohort, tumors classified as class 6 were mainly non-responders to PD-1 blockade in 313 
comparison to the other LMC classes (P=0.03). Hugo et al. reported that expression of AXL predicts 314 
poor response to PD-1 blockade; the gene expression data revealed significantly higher AXL 315 
expression in class 6 tumors when compared to other classes within their cohort (Figure 5G). 316 
Similarly, for the cohort reported by Ulloa-Montoya et al., class 6 tumors showed a significantly higher 317 
proportion of non-responders to MAGE-A3 immunotherapy in comparison to other classes. The cohort 318 
reported by Riaz et al. was predominantly composed of non-responders to anti-CTLA-4 further treated 319 
with PD-1 blockade but LMC classes were not convincingly predictive but class 3 predicted poor 320 
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prognosis, which was consistent with the LMC dataset when compared to good prognosis class 1 321 
(Figure 5H).  322 
 323 
Discussion 324 
In this study, transcriptome classification was performed utilising a large population-ascertained 325 
cohort of primary melanomas, revealing classes having prognostic value in stage I disease. In stage I 326 
tumors, the LMC signature predicted outcome comparably to AJCC staging including SNB. 327 
Furthermore, evidence suggests that the signature predicted outcome in patients treated with 328 
immunotherapies. 329 
Given the rising incidence of early stage tumors and the cost of adjuvant therapies to health services 330 
and to patients in terms of toxicity, there is an urgent need to identify better prognostic and predictive 331 
biomarkers for early stage disease. When previous gene signatures were applied to the LMC (3,8), 332 
the signatures robustly predicted outcome when the dataset was analysed as a whole, but failed to do 333 
so in stage I tumors alone. Although the full Gerami signature was not available, analysing the 334 
prognostic value of genes reported in that study (6) showed that the genes were predictive of 335 
prognosis in the whole LMC dataset but not in stage I tumors. In this work, a six-class signature 336 
(Supplementary data file) was identified which was not only prognostic in the whole LMC dataset but 337 
also in patients diagnosed at AJCC stage I. The prognostic value of the LMC signature was validated 338 
in an independent cohort of primary melanoma built in Lund (4) although the number of stage I cases 339 
in this cohort was insufficient to allow replication of the signature’s prognostic value in stage I disease. 340 
The LMC signature showed limited overlap with the Lund and TCGA signatures. When comparing it 341 
with previously identified immunome clusters by our group (13), two LMC classes strongly overlapped 342 
with immune subgroups. The non-overlapping classes could not be clearly discriminated using the 343 
immunome clusters suggesting that these LMC classes are driven by different genomic mechanisms. 344 
Comparison of LMC signature genes with Gerami genes indicated a biological pathway overlap as 345 
Gerami genes were found to be strongly correlated with LMC classes 3 and 5. 346 
Although SNB is an important melanoma staging tool, the surgery is associated with morbidity 347 
(33,34). In the LMC, SNB was observed to be of prognostic value in the whole dataset and in stage I 348 
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tumors. However, the LMC signature performed just as well. Given the morbidity of SNB, it may be 349 
argued that the LMC signature should be tested in an independent study as a possible alternative to 350 
this procedure especially in stage I disease where the likelihood of a positive result is overall low and 351 
must be weighed against morbidity. 352 
In melanoma, increased immune gene expression has been consistently shown to predict good 353 
prognosis (5,9,13,35). However, a subset of tumors (LMC class 6) was observed which, despite 354 
showing immune gene expression, resulted in the patient’s early death. Further biological 355 
characterisation of this class identified copy number amplifications and increased expression of JUN. 356 
Ramsdale et al. have shown that JUN promotes an invasive cell phenotype through activation of the 357 
EMT pathway (36), and a higher scoring EMT signature in LMC class 6 confirmed increased activity 358 
of the EMT pathway in this class. Riesenberg et al. have reported that increased JUN expression 359 
leads to pro-inflammatory and stress signals that promote cytokine expression in coordination with 360 
NF-B (37). Again, these findings are consistent with the presented transcriptomic observations of 361 
JUN and NFKB1 in defining LMC class 6 (Figure 5B, 5E). There was insufficient tissue to carry out 362 
immunohistochemistry for JUN, therefore JUN protein expression in the TCGA dataset was examined 363 
and confirmed a positive correlation between JUN gene transcription and protein expression 364 
(Supplementary figure S7). Collectively, these data are indicative of copy number gains resulting in 365 
both increased gene expression and transcriptional activity of JUN in LMC class 6 tumors, although 366 
further proteomic studies would be required to confirm this.  367 
The LMC signature was associated with response to immunotherapies; specifically, class 6 368 
associated with poor outcome in two of the three tested datasets. None of these data sets are 369 
sufficiently large to make clear inferences. It is of note that the expression of AXL, a known marker for 370 
immune evasion, was significantly upregulated in LMC class 6 in metastatic melanoma samples in the 371 
Hugo data set.  372 
The inherent strength of this study is the relatively large size of the population ascertained cohort. A 373 
corresponding limitation is the lack of a well powered AJCC stage I dataset to allow independent 374 
replication of the signature in stage I melanoma. Another limitation of this study is that only one-third 375 
of LMC patients had a SNB, limiting the power to compare staging tests. The LMC recruitment period 376 
preceded the advent of both immunotherapy and targeted therapy, and only a very small number of 377 
the study participants have been treated with these drugs. Excluding the samples from these 378 
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participants showed no modifying effect of such treatments on MSS in the LMC dataset (data not 379 
shown). 380 
 381 
In conclusion, this study presents a novel signature with demonstrated prognostic value similar in 382 
magnitude to that of AJCC staging of melanoma, but having added value in stage I melanoma. The 383 
data further confirm that AJCC stage largely captures biological variation associated with survival. 384 
The LMC class signature prognostic value was similar to that of SNB in the whole dataset (where their 385 
effects were additive) and in stage I disease. The signature predicted poor outcome in patients 386 
receiving immunotherapies and in particular identified high-JUN/high-AXL as a tumor phenotype with 387 
poor prognosis in early and advanced stage melanoma albeit in very small datasets. This signature 388 
has the potential to be trialled as a biomarker in clinical monitoring programs and may help in early 389 
identification of patients who may or may not benefit from adjuvant therapies. 390 
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Sex : male n (%) 310 (45) 39 (55) 51 (42) 34 (47) 56 (39) 55 (40) 75 (52) 0.07 
Tumor site: limbs n (%) 289 (42) 37 (52) 58 (48) 26 (36) 58 (41) 64 (47) 46 (32) 0.03 
Age at diagnosis (years) m(r) 58 (18, 81) 59 (21,76) 59 (22,79) 60 (20,77) 58 (18,81) 53 (25,76) 59 (22,81) 0.03 
Breslow thickness (mm) m(r) 2.3 (0.3, 20) 1.7 (0.7, 5.5) 2.1 (0.8, 8.9) 3.2 (0.8, 20) 2.3 (0.3, 15) 1.8 (0.7, 12) 3.0 (0.8, 18) 9 × 10
-14
 





























Ulceration (present) n (%) 228 (33) 16 (23) 32 (26) 30 (41) 53 (37) 38 (28) 59 (42) 0.01 
Mitotic rate (/mm
2
) 1 (0,25) 0 (0,11) 1 (0,17) 2 (0,25) 1 (0,13) 1 (0,12) 1 (0,18) 0.002 



























BRAF mutant yes (%) 266 (47) 26 (43) 38 (30) 23 (40) 44 (36) 63 (59) 72 (61) 6 × 10
-5
 
NRAS mutant yes (%) 138 (25) 8 (14) 35 (34) 17 (30) 41 (34) 20 (19) 17 (15) 3 × 10
-4
 
aThe associations were tested using Pearson’s chi-squared test for categorical variables and the Kruskal-Wallis test for continuous variables. Symbol n is the 508 
number of samples, m is the median and r is the range.  b 7 patients had mucosal melanoma and, although they were classified, they were not included in 509 
survival analyses. Their AJCC stage was not reported. Each of LMC class 2 and 4 contained 2 of these, while class 3, 5 and 6 had 1 each.   510 
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Figure legends 511 
Figure 1: Analysis workflow of the study 512 
 513 
Figure 2: Replicating Lund and TCGA signatures using LMC dataset. Kaplan-Meier plots showing the 514 
Melanoma-specific survival (MSS) for (A) Lund 4-classes (HI- high-immune, NL- normal-like, Pigm.- 515 
pigmentation, Prolif.- proliferative ), (B) Lund 2-grades (low grade and high grade) and (C) TCGA 3-516 
classes (immune, keratin, MITF low) across the whole LMC dataset. In LMC stage I subset, Kaplan-517 
Meier plots showing the MSS for (D) Lund 4-classes, (E) Lund 2-grades, and (F) TCGA 3-classes. 518 
Pvalues are from log-rank test. Samples which could not be classified into any of the classes were not 519 
used in survival analysis. 520 
 521 
Figure 3: Defining LMC signature and its prognostic value. (A) The area under the CDF and its 522 
relative change with increasing k. The delta area graph shows little variation at k=6. Heatmap of 523 
consensus matrices at k=5 and 6. The blue color indicates high consensus score and the white color 524 
indicates low consensus (B) Kaplan-Meier plot showing the MSS for the six classes in (B) the whole 525 
LMC dataset, (C) the LMC stage I, and (D) relapse-free survival in the Lund cohort (Pvalue from log-526 
rank test, or Wald test for two-groups comparison). Seven mucosal tumors were excluded from 527 
analysis. (E) ROC curves comparing the prognostic value of the LMC signature to that of Sentinel 528 
Node Biopsy (SNB) in the whole dataset. The AUCs for LMC class+ stage pre-SNB and stage post-529 
SNB were not significantly different (DeLong’s test P=0.7). (F) The ROC curve comparing prognostic 530 
value of LMC signature with SNB in the stage I pre-SNB group. All but one patient were stage IB pre-531 
SNB, therefore AUC for LMC signature alone was compared to stage post-SNB and the difference 532 
was not significant (DeLong’s test P=0.7). The difference in AUCs between stage post-SNB alone and 533 
LMC class +stage post-SNB was also not significant (DeLong’s test P=0.1). 534 
 535 
Figure 4: Biological characterization of the six LMC classes. (A) The heatmap shows gene expression 536 
across the classes with tumor samples placed in columns and genes in rows. Blue depicts low 537 
expression and red depicts high expression. Each gene expression was standardized to mean 0 and 538 
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standard deviation 1. The up- and down-regulated nodal genes identified in network analyses are 539 
shown under the heatmap. The barplot shows the overlap between the LMC classes and (B) Lund 4-540 
classes (HI- high-immune, NL- normal-like, Pigm- pigmentation, Prolif- proliferative), and (C) TCGA 3-541 
classes. The samples that could not be classified into the Lund 4-classes and TCGA 3-classes were 542 
labelled here as Uncls. (D) The modules (defined by a list of differentially upregulated genes) 543 
associated with melanoma-specific biological pathways as identified by the Lund group (29). Boxplots 544 
of immune and cell cycle module scores (standardized expressions) within the 6 LMC classes and 545 
correlation matrix of immune, cell cycle, MITF, stroma and interferon module scores. The module 546 
score variation across the classes was tested using the Kruskal-Wallis test. 547 
 548 
Figure 5: Biological characterization of LMC class 6 and association with response to immunotherapy. 549 
(A) Network of upregulated genes in the LMC class 6 with key genes (highest betweenness centrality) 550 
shown as large circles. Sub-networks are shown in different colors. (B) Expression of JUN across the 551 
six LMC classes (Pvalue from Kruskal-Wallis test). (C) JUN copy number alterations in LMC class 6 552 
vs other classes. (D) The 6-gene based EMT score in tumors across the six LMC classes (Pvalue 553 
from Kruskal-Wallis test). (E) The gene expression of NFKB1 across the 6 LMC classes (Pvalue from 554 
Kruskal-Wallis test). (F) The LMC classes association with response to immunotherapy in three 555 
cohorts (Pvalue from Fisher’s exact test). Patients in these cohorts were classified into the 6 LMC 556 
classes by the NCC method.  (G) Expression of AXL across the six LMC classes in the Hugo Cohort 557 
dataset (Pvalue from Mann–Whitney U test). (H) Kaplan-Meier plot showing survival curves of LMC 558 
class 1, class 3, and class 6 in the Riaz Cohort. Other LMC classes had <5 samples and were 559 
excluded. 560 
  561 
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